• NanoViricides Inc., of West Haven, Conn., closed its previously announced sale of $2.5 million worth of Series B convertible preferred stock to Seaside 88 LP. Seaside purchased 250,000 shares at $10 per share. Net proceeds of $2.3 million will help NanoViricides advance its antiviral pipeline.
